Related Experiment Video
Updated: May 8, 2026
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
Serum m 30 levels reflects ulcerative colitis activity
Bora Aktaş1, Akif Altınbaş, Omer Başar
1*Department of Gastroenterology, Dişkapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey; †Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Turkey; and ‡Department of Biochemistry, Dişkapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey.
Background:
Apoptosis plays a role in epithelial and mucosal injury, which is 1 of the mechanisms in the pathogenesis of ulcerative colitis. Apoptotic cells increase as a result of injured mucosa in ulcerative colitis and serum M 30 levels increase in epithelial cell apoptosis. In this study, we aimed to evaluate the relation between M 30 serum levels and ulcerative colitis activity.
Methods:
Eighty patients with ulcerative colitis and 40 healthy controls were enrolled into the study. The patient group consisted of 31 extensive colitis, 30 left-sided colitis, and 19 proctitis. The activity of ulcerative colitis was determined with clinical and endoscopic findings. Serum M 30 levels, acute phase reactants, and biochemical tests were analyzed in all subjects.
Results:
Serum M 30 levels in patients with active ulcerative colitis were significantly higher when compared with the healthy controls (165.6 ± 60.6 and 129.6 ± 37.4; P = 0.003). Serum M 30 levels in active left-sided colitis patients was significantly higher when compared with patients in remission phase (180.6 ± 58.5, 141.5 ± 35.4; P = 0.044). When we exclude patients with ulcerative proctitis, M 30 levels in active ulcerative colitis patients were significantly higher than that the patients in remission phase (174.0 ± 63.5, 135.0 ± 29.9; P = 0.017).
Conclusions:
We found that M 30 levels increase in patients with active ulcerative colitis. Our findings support the role of apoptosis demonstrated by serum M 30 levels in the pathogenesis of active ulcerative colitis.
Insights
Serum M 30 levels are elevated in active ulcerative colitis, indicating increased epithelial cell apoptosis. This finding supports apoptosis's role in the pathogenesis of active ulcerative colitis, offering a potential biomarker for disease activity.
Area of Science:
- Gastroenterology
- Cell Biology
- Immunology
Background:
- Ulcerative colitis pathogenesis involves epithelial and mucosal injury.
- Increased epithelial cell apoptosis is observed in ulcerative colitis.
- Serum M 30 levels correlate with epithelial cell apoptosis.
Purpose of the Study:
- To investigate the relationship between serum M 30 levels and ulcerative colitis activity.
- To assess M 30 as a potential biomarker for active disease.
Main Methods:
- Eighty ulcerative colitis patients and 40 healthy controls were recruited.
- Ulcerative colitis activity was assessed clinically and endoscopically.
- Serum M 30 levels, acute phase reactants, and biochemical tests were analyzed.
Main Results:
- Serum M 30 levels were significantly higher in active ulcerative colitis patients compared to controls.
- Active left-sided colitis patients showed higher M 30 levels than those in remission.
- Excluding proctitis, active ulcerative colitis patients had significantly higher M 30 levels than those in remission.
Conclusions:
- Serum M 30 levels are elevated in active ulcerative colitis.
- These findings support the role of apoptosis in active ulcerative colitis pathogenesis.
- Serum M 30 may serve as a biomarker for ulcerative colitis activity.
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Serum Laboratory Studies, Stool Test, Breath Test
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...